Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
Items 801–900 of 1,000
Lin, B., Siskin, M., Wang, B., & Natarajan, S. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10285-z · Cited by 17
“While RCT data in HFpEF patients for angiotensin receptor-neprilysin inhibitors (ARNIs) and SGLT2 inhibitors are limited, they suggest improvement in QOL [5] and QOL and exercise tolerance [7, 9], respectively.”
BackgroundWang, J., Li, J., Lou, A., Lin, Y. H., Xu, Q., Cui, W., Huang, W., Wang, G., Li, Y., Sun, J., et al. (2023) · FEBS Journal · doi:10.1111/febs.16696 · Cited by 17
Self-citationGorter, T. M., van Veldhuisen, D. J., Mulder, B. A., Arita, V. A., van Empel, V. P. M., Manintveld, O. C., Tieleman, R. G., Maass, A. H., Vernooy, K., Gelder, I. C. V., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113682 · Cited by 16
NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure
Habeeb, W. A., Tash, A. A., Elasfar, A., Almasood, A. S., Bakhsh, A., Elshaer, F., Ayoubi, F. A., Alghalaini, K., Alqaseer, M., Alhussein, M., et al. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1334 · Cited by 25
Lee, V., Zheng, Q., Toh, D., Pua, C. J., Bryant, J., Lee, C., Cook, S. A., Butler, J., Díez, J., Richards, M., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1248468 · Cited by 16
“Importantly, this study will provide possible mechanistic insights into the clinical benefits of sacubitril/ valsartan in HF as observed in the pivotal PARADIGM-HF (7) and PARAGON-HF (27) trials.”
BackgroundAbubakar, M., Saleem, A., Hajjaj, M., Faiz, H., Pragya, A., Jamil, R., Salim, S. S., Lateef, I. K., Singla, D. K., Ramar, R., et al. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10369-4 · Cited by 17
“In the PARAGON-HF trial, sacubitril-valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), showed benefits for women but not men [48].”
de la Espriella, R., Wahlberg, K. J., Infeld, M. M., Palau, P., Núñez, E., Sanchís, J. M., Meyer, M., & Núñez, J. E. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3107 · Cited by 16
The Interplay of Comorbidities in Chronic Heart Failure: Challenges and Solutions
Agress, S., Sheikh, J. S., Ramos, A. A. P., Kashyap, D., Razmjouei, S., Kumar, J., Singh, M., Lak, M. A., Osman, A., & Haq, M. Z. U. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x289572240206112303 · Cited by 19
Optimising Transitional Care Following a Heart Failure Hospitalisation in Australia
Sindone, A. P., Driscoll, A. L., Audehm, R. G., Sverdlov, A. L., McVeigh, J., Chan, W. P. A., Hickey, A., Hopper, I., Chang, T., Maiorana, A., et al. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.11.029 · Cited by 16
Tuttle, M. L., Fang, J. C., Sarnak, M. J., & McCallum, W. I. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151516 · Cited by 18
C-type natriuretic peptide (CNP): The cardiovascular system and beyond
Dickinson, Y., Moyes, A. J., & Hobbs, A. J. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108708 · Cited by 16
Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
Rowe, S. J., Paratz, E. D., Fahy, L., Janssens, K., Spencer, L. W., D’Ambrosio, P., Strange, G., Prior, D., Playford, D. A., & Gerche, A. L. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101444 · Cited by 16
Shahid, I., Khan, M. S., Butler, J., Fonarow, G. C., & Greene, S. J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10481-7 · Cited by 16
“…Outcomes in HF With Preserved Ejection Fraction) trial of sacubitril/valsartan versus valsartan where despite an overall neutral trial result, there was a potential benefit of sacu-bitril/valsartan among individuals with an LVEF between 45 to 57% (primary endpoint HR 0.78, 95% CI: 0.64–0.95) [33].”
InfluentialDrug Discovery and Development for Heart Failure Using Multi-Omics Approaches
Rasooly, D., Pereira, A. C., & Joseph, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062703 · Cited by 17
Russo, D., Musumeci, B., & Volpe, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1766 · Cited by 16
Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials
Huang, Y., Zhang, Y., Ma, L., Zhou, H., Fang, C., & Chen, C. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001049 · Cited by 16
Charuel, É., Ménini, T., Bedhomme, S., Pereira, B., Piñol‐Domenech, N., Bouchant, S., Boussageon, R., Bœuf-Gibot, S., & Vaillant-Roussel, H. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.844 · Cited by 16
Sudden cardiac death in patients with myocardial infarction: 1.5 primary prevention
Feng, Y., & Feng, X. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203087 · Cited by 18
“In addition, sacubitril/valsartan also performed better than valsartan in reducing hospitalization rates in HFpEF patients [86].”
BackgroundRenal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis
Barbosa, C. V., Lang, H., Melk, A., & Schmidt, B. M. W. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac001 · Cited by 18
Pintér, A., Behon, A., Veres, B., Merkel, E. D., Schwertner, W. R., Kuthi, L. K., Masszi, R., Lakatos, B. K., Kovács, A. D., Becker, D. J., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020517 · Cited by 16
“Serum NT-proBNP levels also confirmed that this cohort had an advanced heart failure with a mean value of 1500 pg/mL, which was significantly higher than described in large-scale RCTs [34].”
ResultSelf-citationAgeev, F. T., & Ovchinnikov, A. G. (2022) · Kardiologiia · doi:10.18087/cardio.2022.7.n2058 · Cited by 16
Lin, Y., Cai, Z., Yuan, J., Liu, H., Pang, X., Chen, Q., Tang, X., Geng, Q., & Dong, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01679-2 · Cited by 17
“Large RCTs focused on HFpEF outcomes, including PEP-CHF (perindopril) [13], CHARM-Preserved (candesartan) [11], I-PRESERVE (irbesartan) [15], TOPCAT (spironolactone) [20], DIG-Preserved (digoxin) [14], J-DHF (carvedilol) [19], VITALITY-HFpEF (vericiguat) [22], and PARAGON-HF (sacubitril/valsartan) [21], have failed to…”
Riccardi, M., Tomasoni, D., Vizzardi, E., Metra, M., & Adamo, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10280-4 · Cited by 18
Lorenzi, A. B. D., Kaplinsky, E., Zambrano, M. R., Chaume, L. T., & Rosas, J. M. (2023) · Drugs in Context · doi:10.7573/dic.2022-7-1 · Cited by 19
A big STEP for treatment of heart failure with preserved ejection fraction
Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Dhingra, N. K., & Kosiborod, M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.003 · Cited by 16
Self-citationCoagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction
Karaban, K., Słupik, D., Reda, A., Gajewska, M., Rolek, B., Borovac, J. A., Papakonstantinou, P. Ε., Bongiovanni, D., Ehrlinder, H., Parker, W. A., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102127 · Cited by 19
Dani, S. S., Ganatra, S., & Vaduganathan, M. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.067 · Cited by 18
Aimo, A., Senni, M., Barison, A., Panichella, G., Passino, C., Bayés‐Genís, A., & Emdin, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10228-8 · Cited by 19
“In a side-by-side comparison between the PARAGONHF trial and the EMPEROR-Preserved trial [64], baseline characteristics were similar, including renal failure and diabetes prevalence, yet the former had higher EF (> 45% for eligibility, mean 57.5 ± 8.0”
BackgroundInfluentialSelf-citationMinotti, G., Menna, P., Camilli, M., Salvatorelli, E., & Levi, R. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.02.002 · Cited by 18
The atrial flow regulator: current overview on technique and first experience
Paitazoglou, C., & Bergmann, M. W. (2020) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944720919577 · Cited by 16
Women and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 17
“111”
Efficacy and Safety of Heart Failure Treatment According to Frailty Status: A Systematic Review
Nijskens, C. M., Handoko, M. L., Remmelzwaal, S., Ziesemer, K. A., & Muller, M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042367 · Cited by 16
“31 Spironolactone in HFpEF did not have a greater effect on the primary composite outcome (HF worsening or cardiovascular death) than placebo in the original study, 32 and this was consistent regardless of frailty (no significant interaction).”
Virani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 34
RetractedAging and metabolism in HFpEF: Pathophysiology and therapeutic implications
Ye, M., Feng, S., Xu, Z., He, W., Liu, C., & Zhu, W. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156460 · Cited by 16
Boehmer, A. A., Ninni, S., Heijman, J., Dobrev, D., & Nattel, S. (2026) · Physiological Reviews · doi:10.1152/physrev.00020.2025 · Cited by 17
Zimerman, A., da Silveira, A. D., Borges, M. S., Engster, P. H. D. B., Schaan, T., de Souza, G. C., de Souza, I. P. M. A., Ritt, L. E. F., Stein, R., Berwanger, O. B., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14287 · Cited by 18
Tecce, N., de Alteriis, G., de Alteriis, G., Verde, L., Tecce, M. F., Colao, A., & Muscogiuri, G. (2024) · Healthcare · doi:10.3390/healthcare12070753 · Cited by 17
Balestrieri, G., Limonta, R., Ponti, E., Merlo, A., Sciatti, E., D’Isa, S., Gori, M., Casu, G., Giannattasio, C., Senni, M., et al. (2024) · Cardiac failure review · doi:10.15420/cfr.2023.13 · Cited by 16
“67 The primary endpoint was a composite of total HF hospitalisation or CV death.”
Self-citationDoiron, J. E., Xia, H., Yu, X., Nevins, A., LaPenna, K. B., Sharp, T. E., Goodchild, T. T., Allerton, T. D., Elgazzaz, M., Lazartigues, E. D., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16493 · Cited by 15
Self-citationHabel, N., Infeld, M. M., Lustgarten, D. L., & Meyer, M. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.064 · Cited by 16
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 17
Haim, I. R., Gruber, A., Kazma, N., Bashai, C., Kinsbruner, H. L., & Caspi, O. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011690 · Cited by 17
Bellicini, M. G. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04097-w · Cited by 15
New and emerging cardiovascular and antihypertensive drugs
Chrysant, S. G., & Chrysant, G. S. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1810232 · Cited by 15
“term trial (PARAGON) of 4822 patientswith HFpEF (EF ≥ 45%) for 35 months [15].”
BackgroundFeld, Y., Reisner, Y., Meyer-Brodnitz, G., & Hoefler, R. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10104-x · Cited by 15
Valvular Disease and Heart Failure with Preserved Ejection Fraction
Fan, Y., & Lee, A. P. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.005 · Cited by 15
Chen, Y.-J., Chien, C., Chiang, C., Chen, C.-H., & Cheng, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126617 · Cited by 18
“than mid-range EF, may be a more appropriate term given the fact that the Prospective Comparison of angiotensin receptor-neprilysin inhibitor (ARNI) with angiotensin-receptor blockers Global Outcomes in HFpEF trial indicated that patients with LVEF lower than normal can still probably benefit from such therapies [4].”
BackgroundAbumayyaleh, M., Pilsinger, C., El‐Battrawy, I., Kummer, M., Kuschyk, J., Borggrefe, M. M., Mügge, A., Aweimer, A., & Akın, İ. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214989 · Cited by 15
“In patients with heart failure with preserved ejection fraction (HFpEF), ARNI did not reduce the total hospitalization rate due to HF and deaths from cardiovascular causes [4].”
BackgroundHeart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
Vaz-Salvador, P., Adão, R., Vasconcelos, I., Leite-Moreira, A. F., & Brás‐Silva, C. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07306-8 · Cited by 17
“Several post hoc analyses of the recent sacubitril-valsartan PARAGON trial (NCT01920711) point in this exact direction—despite the trial’s failure to meet its primary endpoint of reducing the number of composite events of cardiovascular death and total hospitalizations related to HF [25], there are studies showing sig…”
BackgroundResultTakada, T., Matsuura, K., Minami, Y., Abe, T., Yoshida, A., Kishihara, M., Watanabe, S., Shirotani, S., Jujo, K., & Hagiwara, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-12823-z · Cited by 15
Mancusi, C., Lembo, M., Manzi, M. V., Basile, C., Fucile, I., & Morisco, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185377 · Cited by 15
“Latest research has also recognized that sodium-glucose cotransporter 2 inhibitor (SGLT2-i) is an effective strategy in reducing combined end point for hospitalization and death, while sacubitril/valsartan are effective in reducing the hospitalization for heart failure [112,113].”
BackgroundYuyun, M. F., Kinlay, S., Singh, J. P., & Joseph, J. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14248 · Cited by 20
Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction
Musse, M., Lau, J. D., Yum, B., Pinheiro, L. C., Curtis, H., Anderson, T. S., Steinman, M. A., Meyer, M., Dorsch, M. P., Hummel, S. L., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.01.050 · Cited by 15
Leontsinis, I., Farmakis, D. T., Avramidis, D., Andrikou, E., Valatsou, A., Gartzonikas, I. K., Doundoulakis, I., Zarifis, Ι., Karpouzis, I., Kafkala, K., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.03.006 · Cited by 16
Shen, L., Lee, M. M. Y., Jhund, P. S., Granger, C. B., Anand, I. S., Maggioni, A. P., Pfeffer, M. A., Solomon, S. D., Swedberg, K. B., Yusuf, S., et al. (2024) · JAMA · doi:10.1001/jama.2024.6774 · Cited by 15
Self-citationSuzuki, S., Motoki, H., Kanzaki, Y., Maruyama, T., Hashizume, N., Kozuka, A., Yahikozawa, K., & Kuwahara, K. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12867 · Cited by 16
“Approximately half of all patients with heart failure (HF) have a normal or near normal left ventricular ejection fraction (LVEF), a condition known as HF with preserved ejection fraction (HFpEF).1–4 Although the prognosis of HF with reduced ejection fraction (HFrEF) has improved significantly in recent decades due to…”
BackgroundInfluentialA Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction
Vaishnav, J., & Sharma, K. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.12.013 · Cited by 15
Natural language processing to adjudicate heart failure hospitalizations in global clinical trials
Marti-Castellote, P. M., Reeder, C., Claggett, B., Singh, P., Lau, E. S., Khurshid, S., Batra, P., Lubitz, S. A., Maddah, M., Vardeny, O., et al. (2025) · Circulation: Heart Failure · doi:10.1161/circheartfailure.124.012514 · Cited by 14
Self-citationAssociation of Female Menopause With Atrioventricular Mechanics and Outcomes
Sung, K., Chandramouli, C., Lo, C., Tsai, J., Lai, Y., Hsiao, C., Tsai, S., Yun, C., Hung, T., Kuo, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.804336 · Cited by 16
“post-menopausal women, and (3) pre- vs.”
Self-citationLeite, M., Sampaio, F., Saraiva, F. A., Diaz, S. O., Barros, A. S., & Fontes‐Carvalho, R. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14284 · Cited by 14
Zhang, X.-J., Liu, C.-C., Li, Z., Ding, L., Zhou, Y. N., Zhang, D.-J., Zhang, Y., Hou, S.-T., & Ma, R. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01284-1 · Cited by 14
“For instance, Sac/Val was proven to have cardiovascular protection effects [10].”
BackgroundSzabo, B. A., Benson, L., Savarese, G., Hage, C., Fudim, M., Devore, A., Pitt, B., & Lund, L. H. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.02.021 · Cited by 14
Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
Lucà, F., Oliva, F. G., Abrignani, M. G., Fusco, S. A. D., Gori, M., Giubilato, S., Ceravolo, R., Temporelli, P. L., Cornara, S., Rao, C. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051375 · Cited by 16
Bonacchi, G., Rossi, V. A., Garofalo, M., Mollace, R., Uccello, G., Pieragnoli, P., Checchi, L., Perrotta, L., Voltolini, L., Ricciardi, G., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12050981 · Cited by 14
“In the sacubitril/valsartan arm, a preventive effect was observed with a lower incidence of worsening renal function [90].”
BackgroundNew and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 15
“The subsequent phase 3 trial, PARAGON-HF, randomized 4,822 individuals with NYHA class II–IV HF and LVEF ≥ 45% to receive sacubitril– valsartan or valsartan 34 .”
Segev, A., Ishay, R. T.-B., Metra, M., Maor, E., Freimark, D., Younis, A., Beigel, R., Matetzky, S., & Grupper, A. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02620-9 · Cited by 14
Song, Y., Zhao, X., Wang, L.-J., Ning, T., Chen, M.-T., Liu, P., Chen, S., & Zhao, X. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02720-w · Cited by 14
“Consequently, treatment strategies for HFpEF are complex and have garnered significant clinical attention in recent years, yet there remains a lack of clinical predictive models for HFpEF following MI [6].”
InfluentialMatsumoto, C., Nagai, M., Shinohara, K., Morikawa, N., Kai, H., & Arima, H. (2025) · Hypertension Research · doi:10.1038/s41440-025-02240-w · Cited by 15
“In cases where only subgroup-speci fi c mean BP changes (e.g., by sex) were reported rather than overall mean changes, we calculated the overall mean BP change using weighted averages and used it for the estimation [4, 16].”
InfluentialOptimizing the Primary Prevention of Sudden Cardiac Death in Patients With Heart Failure
Wallace, N., Wong, K., Desmarais, T., Park, J. J., Krummen, D. E., Lim, W., Campagnari, C., Yagil, A., & Greenberg, B. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.05.061 · Cited by 16
Heart failure with preserved ejection fraction: insights from recent clinical researches
Kim, M., & Park, S. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.104.e1 · Cited by 14
Shen, J., & Xie, X.-J. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000858 · Cited by 16
Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system
Nicolaou, P. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173961 · Cited by 14
Bayesian Analyses of Cardiovascular Trials—Bringing Added Value to the Table
Brophy, J. M. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.03.014 · Cited by 20
Camafort, M., Jhund, P. S., Formiga, F., Castro, A., Arévalo‐Lorido, J. C., Sobrino-Martínez, J., Manzano, L., Díez‐Manglano, J., Aramburu, Ó., Pérez‐Barquero, M. M., et al. (2021) · Revista Clínica Española · doi:10.1016/j.rce.2020.11.010 · Cited by 14
Self-citationRationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
Graziani, F., Lillo, R., & Crea, F. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.678530 · Cited by 15
Geest, B. D., & Mishra, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159022 · Cited by 14
Nuechterlein, K., AlTurki, A., Ni, J., Martínez‐Sellés, M., Martens, P., Russo, V., Backelin, C. N., & Huynh, T. T. (2021) · CJC Open · doi:10.1016/j.cjco.2021.09.009 · Cited by 14
Teo, Y. N., Teo, Y. H., Syn, N. L. X., Yoong, C. S. Y., Cheong, A. J. Y., Wee, C. F., Lim, Y. C., Lee, C., Yeo, T., Chai, P., et al. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01098-3 · Cited by 14
Pitt, B., Ferreira, J. P., & Zannad, F. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab717 · Cited by 14
Self-citationLund, L. H., Savarese, G., Venkateshvaran, A., Benson, L., Lundberg, A., Donal, E., Daubert, J., Oger, E., Linde, C. M., & Hage, C. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13705 · Cited by 14
“06}.(10) However, there was a significant treatment–LVEF interaction.”
BackgroundResultInfluentialSharma, A., Blasio, M. J. D., & Ritchie, R. H. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15820 · Cited by 14
Sakai, T., Motoki, H., Suzuki, S., Fuchida, A., Takeuchi, T., Otagiri, K., Kanai, M., Kimura, K., Minamisawa, M., Yoshie, K., et al. (2022) · Heart and Vessels · doi:10.1007/s00380-022-02067-2 · Cited by 14
“Moreover, in the PARAGON-HF trial, only women who were treated with ARNI exhibited risk reduction of the primary outcome [5].”
BackgroundMethodWang, R., Ye, H., Ma, L., Wei, J., Wang, Y., Zhang, X., & Wang, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.890481 · Cited by 14
“PARAGON-HF (19) 4 822 26 months HFpEF NYHA II-IV,EF ≥ 45% 72.”
SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction
Requena-Ibáñez, J. A., Santos‐Gallego, C. G., Zafar, M. U., & Badimón, J. J. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07371-7 · Cited by 17
“In the PARAGON-HF trial [5] (Fig.”
Heart Failure and Cardiomyopathies: CT and MR from Basics to Advanced Imaging
Palumbo, P., Cannizzaro, E., Palumbo, M. M., Cesare, A. D., Bruno, F., Acanfora, C., Arceri, A., Evangelista, L., Arrigoni, F., Grassi, F., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12102298 · Cited by 15
“Moreover, different studies have demonstrated that mild and reduced phenotypes derive similar benefits from similar therapeutic treatments, suggesting that they may belong to a similar category [28,29,40,41].”
BackgroundMujadzic, H., Prousi, G. S., Napier, R., Siddique, S. M., & Zaman, N. (2022) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2022.130905 · Cited by 14
Anderson, T., Hummel, S. L., & Konerman, M. C. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2022.07.001 · Cited by 17
Longitudinal Changes in Left Ventricular Diastolic Function in Late Life
Zhao, L., Zierath, R., Claggett, B. L., Dorbala, P., Matsushita, K., Kitzman, D. W., Folsom, A. R., Konety, S., Mosley, T. H., Skali, H., et al. (2023) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2023.02.022 · Cited by 14
Self-citationOhte, N., Kikuchi, S., Iwahashi, N., Kinugasa, Y., Dohi, K., Takase, H., Masai, K., Inoue, K., Okumura, T., Hachiya, K., et al. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae033 · Cited by 14
Stanko, P., Repova, K., Baka, T., Krajcirovicova, K., Aziriova, S., Barta, A., Zórad, Š., Adamcová, M., & Šimko, F. (2024) · Biomedicines · doi:10.3390/biomedicines12040733 · Cited by 15
“…(Prospective Comparison of ARNI (angiotensin receptor-neprilysin inhibitor) with ARB (angiotensin-receptor blockers) Global Outcomes in HF with Preserved Ejection Fraction) trial has not shown any benefit of sacubitril–valsartan in patients who had HF with pre-served ejection fraction [8].”
BackgroundManagement of heart failure with preserved ejection fraction
Gard, E. K., Nanayakkara, S., Kaye, D. M., & Gibbs, H. H. (2020) · Australian Prescriber · doi:10.18773/austprescr.2020.006 · Cited by 15
Covariate adjusted reanalysis of the I-Preserve trial
Ferreira, J. P., Dewan, P., Jhund, P. S., Lorenzo-Almorós, A., Duarte, K., Petrie, M. C., Carson, P. E., McKelvie, R. S., Michel Komajda, N., Zile, M. R., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01632-x · Cited by 14
Self-citationKammerlander, A. A., Nitsche, C., Donà, C., Koschutnik, M., Dannenberg, V., Mascherbauer, K., Schönbauer, R., Zafar, A., Winter, M., Bartko, P. E., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2345 · Cited by 14
Relevance of Neutrophil Neprilysin in Heart Failure
Prausmüller, S., Spinka, G., Arfsten, H., Stasek, S., Rettl, R., Bartko, P. E., Goliasch, G., Strunk, G., Riebandt, J., Mascherbauer, J., et al. (2021) · Cells · doi:10.3390/cells10112922 · Cited by 15
Left Heart Disease-Related Pulmonary Hypertension
Alamri, A. K., Ma, C. L., & Ryan, J. J. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.08.007 · Cited by 14
Liu, X., Wang, G., Xu, Q., Zhang, L., & Liu, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.943377 · Cited by 14
“Of included nine trials, 6 trials (6, 10, 12, 17, 19, 20), including 1 (19) enrolled patients with acute decompensated HF, enrolled patients with HFrEF the others (11, 16, 18) enrolled patients with HFpEF.”
BackgroundNatriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage
Kato, J. (2020) · Peptides · doi:10.1016/j.peptides.2020.170352 · Cited by 15
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials
Marti-Castellote, P. M., Badrouchi, S., Claggett, B. L., Xu, D., Maddah, M., Khurshid, S. S., Vardeny, O., Lewis, E. F., Jhund, P. S., Desai, A. S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.055 · Cited by 14
Self-citationAortic Thoracic Neuromodulation in Heart Failure with Preserved Ejection Fraction
Paolisso, P., Dagan, A., Gallinoro, E., Colle, C. D., Bertolone, D. T., Moyá, A., Pěnička, M., Degrieck, I., Vanderheyden, M., & Bartúnek, J. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14136 · Cited by 13
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.